acr 2020 annual meeting

ACR 2022 Annual Meeting


April 24 – 26, 2022

Accredited CE Information

ACR 2022 Annual Meeting
Sunday, April 24 – Tuesday, April 26, 2022

Learning Objectives

After completing this activity, the participant should be better able to:

  • Recognize key leadership and practice management skills to enhance the value-based care of radiology.
  • Discuss health policy trends impacting the radiology healthcare field.
  • Identify the key legislative issues that affect the radiology profession.
  • Outline critical regulatory information on procedures and guidelines to enhance the practice of radiology.
  • Cite 2-3 examples of current innovative technologies to improve performance and quality.

Physician Accreditation Statement
The American College of Radiology is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

ACR 2022 Credit Designation
The American College of Radiology designates this live activity for a maximum of 4.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ACR 2022 Maintenance of Certification (MOC) Part II: Lifelong Learning and Self-Assessment
The Radiation Oncology Session titled, Advocacy, Economics & Health Policy in Radiation Oncology, is qualified in meeting the criteria for self-assessment toward the purpose of fulfilling requirements in the American Board of Radiology Maintenance of Certification (MOC) Part II: Lifelong Learning and Self-assessment.

This session is eligible for 2.0 SAM credits toward the ABR’s MOC program.

Instructions to Receive Credit, as applicable
In order to successfully complete the activity, participants must, complete an activity evaluation and claim credit commensurate with their participation in the activity. This can be done via ACR’s credit claiming site: https://www.highmarksce.com/acr/claimcredit , utilizing your username and password. An e-mail from alacount@acr.org will be sent with access to the site, along with instructions.

Contact Information
For information about the accreditation of this program, please contact the ACR at alacount@acr.org or carmstrong@acr.org.

Disclosure of Relevant Financial Relationships
The American College of Radiology (ACR) adheres to the policies and guidelines, including the Standards for Integrity and Independence in Accredited CE, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME), stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous. All persons in a position to control the content of an accredited continuing education program provided by ACR are required to disclose all financial relationships with any ineligible company within the past 24 months. All financial relationships reported are identified as relevant and mitigated by ACR in accordance with the Standards for Integrity and Independence in Accredited CE in advance of delivery of the activity to learners. The content of this activity was vetted by ACR to assure objectivity and that the activity is free of commercial bias. All relevant financial relationships have been mitigated by the ACR. 

The following planners and managers have no relevant financial relationships with ineligible companies:

  • Alexis LaCount
  • Carlye Armstrong, CHCP
  • Nazish Khaliq, MS
  • Lori Deitte, MD, FACR
  • David C. Youmans, MD, FACR
  • Loralie D. Ma, MD, PhD, FACR
  • Melody Ballesteros
  • Eugenia Brandt
  • Anne Marie Pascoe
  • Frank Lexa, MD, MBA, FACR
  • Richard Duszak, Jr., MD, FACR
  • Gregory N. Nicola, MD, FACR
  • Angela Kim
  • Theresa Powell
  • Trina Madison Behbahani, CAE
  • Tanvir Rizvi, MD – Independent Content Reviewer

The following planners and managers have the following relevant financial relationships with ineligible companies:

  • Arya Amini, MD: Consulting Fee: Regeneron/Sanofi, HealthHelp; Speakers’ Bureau: AstraZeneca, Takeda Pharmaceuticals; Research Support: RefleXion
  • Rajan T. Gupta, MD: Consulting Fee: Bayer Pharma AG, Invivo Corp., Bard, DxTx Medical, Quibim; Speakers’ Bureau: Bayer Pharma AG
  • Timothy A. Crummy, MD, MHA, FACR: Stock Shareholder: Apple, Amgen, Biogen, Johnson & Johnson, Regeneron

The following moderators have no relevant financial relationships with ineligible companies:

  • Gregory N. Nicola, MD, FACR
  • Frank Lexa, MD, MBA, FACR
  • Richard Duszak, Jr., MD, FACR

The following moderators have the following relevant financial relationships with ineligible companies:

  • Rajan T. Gupta, MD: Consulting Fee: Bayer Pharma AG, Invivo Corp., Bard, DxTx Medical, Quibim; Speakers’ Bureau: Bayer Pharma AG
  • Arya Amini, MD: Consulting Fee: Regeneron/Sanofi, HealthHelp; Speakers' Bureau: AstraZeneca, Takeda Pharmaceuticals; Research Support: RefleXion
  • Darcy Wolfman, MD: Consulting Fee: POCUS PRO

The following faculty members have no relevant financial relationships with ineligible companies:

  • Kristin Brackemyre
  • Bonnie Litvack-Penn, MD, FACR
  • Amy Patel, MD
  • Gregory N. Nicola, MD, FACR
  • Lauren (Golding) Nicola, MD
  • Melissa L. Chen, MD
  • Kurt A. Schoppe, MD
  • Michael Booker, MD, MBA
  • Andrew Moriarity, MD
  • Richard Heller, MD
  • Ezequiel “Zeke” Silva, III, MD, FACR, FSIR, FRBMA, RCC
  • Richard Duszak, Jr., MD, FACR
  • Howard B. Fleishon, MD, MMM, FACR
  • Jacqueline A. Bello, MD, FACR
  • William T. Thorwarth, Jr., MD, FACR
  • Arl Van Moore, MD, FACR
  • Ann K. Jay, MD
  • Lawrence R. Muroff, MD, FACR
  • Carrie Cole
  • Christine Coon
  • Colin J. O’Brien, MD
  • Kirti Magudia, MD, PhD
  • Amar Rewari, MD
  • Paul E. Wallner, DO, FACR
  • Laeton J. Pang, MD, MPH, FACR
  • Najeeb Mohideen, MD, FACR
  • Aaron Bush, MD
  • Brigette McInnis-Day
  • McKinley Glover, MD
  • Dana Smetherman, MD
  • Stephan Ferrara, MD, FSIR, FACR
  • Monica J. Wood, MD

The following faculty members (speakers and content developers) have the following relevant financial relationships with ineligible companies::

  • Tilden L. Childs, III, MD, FACR: Stock Shareholder: Johnson & Johnson, Pfizer, Proctor & Gamble, Kimberly-Clark
  • Sammy Chu, MD, FACR: Stock Shareholder: Johnson & Johnson, Thermo Fischer Scientific, Inc., Stryker Corporation, Guardant Health, Inc.
  • Joshua Hirsch, MD, FACR, FSIR, FSNIS: Consulting Fee: Medtronic, Relievant, Balt, Persica Pharmaceuticals; Stock Options: Artio, Alio, InNeuroCo, Selkirk
  • C. Matthew (Matt) Hawkins, MD: Consulting Fee: Guerbet
  • Alexander M. Norbash, MD, MS, FACR: Scientific Advisor: Stryker, Inc., Penumbra, Inc.; Research Grant: Canon, Inc.
  • Janice M. Newsome, MD: Scientific Advisory Board: Boston Scientific; Consulting Fee: Cook Medical, Hyperfine, Carestream
  • Kristin K. Porter, MD, PhD: Stock Shareholder: Pfizer, Inc.; Consulting Fees: Bracco Diagnostics COVID-19 Advisory Panel